Compare TransMedics Group Inc (TMDX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while Vanguard Total International Stock Index Fund ETF trades at $84.39. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VXUS | |
|---|---|---|
Market Cap | $2.54B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $150.42 | $87.06 |
52-Week Low | $61.99 | $68.24 |
Enterprise Value | $2.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
VXUS trades at $83.07, down 0.36% with a bearish technical signal from moving averages. The ETF provides diversified international exposure to over 8,700 non-U.S. stocks across developed and emerging markets. Recent institutional buying activity includes Greenwood Gearhart increasing its position by 45.8% in Q1 2026. Technical indicators show neutral oscillators but bearish momentum with support at $82 and resistance at $84.
The outlook remains cautious due to global economic uncertainty, though VXUS offers diversification benefits for U.S.-centric portfolios. Key risks include currency fluctuations and emerging market volatility. Analyst sentiment is mixed with some recommending international diversification while others caution about growth/inflation dynamics in global markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
